SPOTLIGHT: Vertex shares dip on trial schedule

Shares of Vertex Pharmaceuticals slid this morning after the company announced new trials of the hep C drug telaprevir, with full data scheduled for mid-2010. Analysts raised red flags last fall when Vertex reported mixed results from a closely watched mid-stage trial. New trials--needed because of earlier trial design flaws--will delay any final approval, allowing competing therapies from Schering-Plough and Johnson & Johnson to beat Vertex to the market. Release | Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.